Idorsia Ltd. · SIX:IDIA
Idorsia — Shareholder Meeting (May 2023)
16 slides from Idorsia's shareholder meeting presentation, May 2023
Slide 1: Annual General Meeting 2023
Annual General Meeting 2023
Slide 2: Opening remarks by the Chairman
Opening remarks by the Chairman
Slide 3: A start-up like no other
A start-up like no other Idorsia has the ideal constellation for bringing successful medicines to patient >10 >20-year Compounds in the pipeline, with half in late-stage development Heritage of drug discovery >1,300 Highly qualified Global professionals Commercial operations in Europe, Japan and the
Slide 4: Our Strategic Priorities
Our Strategic Priorities Our mid-term key priorities to 2 Successfully launch our new products achieve long-term 3 Bring Idorsia to success: sustainable profitability 1 Advance late- stage pipeline 4 Fuel our pipeline with new discoveries 5 Utilize state-of-the-art technologies to drive innovation 4
Slide 5: Liquidity
Liquidity 20 FIRST QUARTER in CHF millions, rounding differences may occur 23 466 466 14 146 116 Cash and Other FX Cash equivalents Cash deposits USD 212 < 12 months 212 26 Cash deposits CHF 320 336 48 > 12 months 212 138 Liquidity @ Liquidity @ Liquidity @ Liquidity @ Dec 31, 2022 Mar 31, 2023 Dec
Slide 6: Profitability target
Profitability target The company is committed to reach sustainable profitability in 2025 with global revenue above CHF 1 billion Based on: • Sales of QUVIVIQ • Sales of PIVLAZ in Japan • Tiered royalties on aprocitentan Excluding unforeseen events 6 Idorsia Annual General Meeting | May 2023
Slide 7: Opening remarks by the Chairman
Opening remarks by the Chairman
Slide 8: Business Review
Worila Business Review
Slide 9: 2022 was a transformative year for Idorsia
2022 was a transformative year for Idorsia 2022 Idorsia became a commercial company… …plus a key year for future growth 1Q 1Q 2Q 2Q 2Q 2Q 4Q 4Q 4Q 4Q Aprocitentan Cenerimod FILING QUVIVIQ NDA filed with Aprocitentan Daridorexant First commercial INITIATION RESULTS Phase 3 US FDA QUVIVIQ QUVIVIQ RESU
Slide 10: Our commercial reach
Our commercial reach Asia Tokyo, Japan Seoul, South Korea Europe North America Allschwil, Switzerland Radnor, Pennsylvania USA Paris, France Montreal, Canada Munich, Germany Milan, Italy Madrid, Spain Stockholm, Sweden London, United Kingdom 10 Idorsia Annual General Meeting | May 2023
Slide 11: QUVIVIQ™ (daridorexant)
QUVIVIQ™ (daridorexant) Daridorexant is available in the US and the first countries in Europe under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union, in Switzerland and in Canada. 11 Idorsia Annual General Meeting | May 2023
Slide 12: PIVLAZ™ (clazosentan)
PIVLAZ™ (clazosentan) Clazosentan is only marketed in Japan under the tradename PIVLAZ™. In other countries, clazosentan is investigational, in development and not approved or marketed. 12 Idorsia Annual General Meeting | May 2023
Slide 13: Our drug discovery engine continues to deliver
Our drug discovery engine continues to deliver Compound Mechanism of action Target indication Status PIVLAZ® Cerebral vasospasm associated with Endothelin receptor antagonist Commercially available as PIVLAZ in Japan. (clazosentan) aneurysmal subarachnoid hemorrhage Commercially available as QUVIVIQ
Slide 14: Momentum building catalysts in 2023
Momentum building catalysts in 2023 2023 1H 1H 1H 1H mid- 2H 2H end- Aprocitentan QUVIVIQ FDA decision QUVIVIQ NDA in US QUVIVIQ QUVIVIQ Lucerastat Launch submission Launch Regulatory Future path in UK in Japan Aprocitentan in Switzerland QUVIVIQ decision decision MAA Secure broader submission in Ca
Slide 15: Our achievements in 2022 provide great momentum going into 2023
Our achievements in 2022 provide great momentum going into 2023 15 Idorsia Annual General Meeting | May 2023
Slide 16: Be prepared for more
Be prepared for more 16 Idorsia Annual General Meeting | May 2023